Phase 2

Who we are

• April 5, 2022

  A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

• April 5, 2022

  Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer

• January 1, 1970

  A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

• January 1, 1970

  Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab

• January 1, 1970

  Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM

• January 1, 1970

  A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

• January 1, 1970

  GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.

• January 1, 1970

  Isunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS)

Previous1415